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Natural History of Arrhythmogenic Right Ventricular
Cardiomyopathy in the Boxer Dog: A Prospective Study
K.M. Meurs, J.A. Stern, Y. Reina-Doreste, A.W. Spier, S.L. Koplitz, and R.D. Baumwart
Background: Boxer arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease that may result in sudden
death or heart failure.
Hypothesis/objectives: To prospectively study the natural history of Boxer ARVC.
Animals: 72 dogs (49 ARVC, 23 controls).
Methods: Boxers >1 year of age were recruited for annual reevaluation. Controls were defined as being ≥6 years of age
and having <50 ventricular premature complex (VPCs)/24 h. ARVC was defined as ≥300 VPCs/24 h in the absence of
other disease. Dogs were genotyped for the striatin deletion when possible. Descriptive statistics were determined for age;
VPC number; annual change in VPC number; and left ventricular (LV) echocardiographic dimensions. Survival time was
calculated.
Results: Controls: median age of 7 years (range, 6–10); number of VPCs 12 (range, 4–32). Median time in study of
6 years (range, 2–9). Seventeen of 23 were genotyped (5 positive, 12 negative).ARVC: median age of diagnosis of 6 (range,
1–11). Median time in study 5 years (range, 3–8). A total of 33% were syncopal and 43/49 were genotyped (36 positive, 7
negative). Yearly change in VPCs was 46 (range, 7,699 to 33,524). Annual percentage change in LV dimensions was 0,
and change in fractional shortening (FS%) was 2%. Two dogs had FS% <20%. Although ARVC dogs died suddenly,
there was no difference in survival time between groups. ARVC median age of survival was 11 years, and for controls was
10 years.
Conclusions/Clinical Importance: Arrhythmogenic right ventricular cardiomyopathy is a disease of middle age and fre-
quently is associated with the striatin deletion. Syncope occurs in approximately 1/3 of affected dogs; systolic dysfunction
is uncommon. The prognosis in many affected dogs is good.
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Arrhythmogenic right ventricular cardiomyopathy(ARVC) is a familial myocardial disease observed
in the adult Boxer dog.1,2 It is characterized by the
presence of ventricular tachyarrhythmias, syncope and,
in a small percentage of dogs, myocardial dysfunction.
It has been shown to be a familial trait that is associ-
ated with a deletion in the striatin gene, in at least
some cases.3 Although affected dogs may experience
sudden cardiac death or progress to congestive heart
failure, many dogs appear to live for years with stable
disease. The disease has been well characterized from
familial, clinical, and pathological perspectives.1–6
However, the natural history of the disease is less well
described.
The objective of this study was to prospectively
characterize the natural history of ARVC in the adult
Boxer dog. Boxer dogs >1 year of age were recruited
for participation in a study requiring annual reevalua-
tion. Affected status for ARVC was defined by the
detection of at least 300 ventricular premature com-
plexes (VPCs) per day in the absence of other systemic
or cardiovascular disease.
Materials and Methods
This study was conducted in accordance with the “Position of
the American Heart Association on Research Animal Use” and
under the guidelines of the Animal Care and Use Committee of
The Ohio State University.
Boxer dogs >1 year of age were prospectively recruited for
participation in a study to evaluate the natural history of Boxer
ARVC. Evaluation included obtaining a clinical history, which
sought a history of syncope, signs consistent with congestive
heart failure or both, and other systemic illness. A physical exam-
ination, echocardiogram, and 24-hour ambulatory electrocardio-
gram (AECG) using a 3-channel transthoracic system were
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ARVC arrhythmogenic right ventricular cardiomyopathy
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LVIDD left ventricular internal diastolic dimension
LVIDS left ventricular internal systolic dimension
PCR polymerase chain reaction
VPC ventricular premature complex
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performed. Owners were asked to return with their dogs on an
annual basis for a follow-up evaluation to include physical exam-
ination, echocardiogram, and AECG until the time of death.
Date and cause of death were recorded when possible.
M-mode echocardiographic measurements were recorded from
2-dimensional guided right parasternal short axis views obtained
with either a 3.5 or 5-MHz transducer with the dog positioned in
right lateral recumbency. Measurements of the left ventricular
internal dimensions and fractional shortening (FS%) were made
in accordance with the American Society of Echocardiography
standards by board- certified veterinary cardiologists or their resi-
dents under supervision of a veterinary cardiologist.7 Dogs were
classified as having myocardial dysfunction or ventricular dilata-
tion, if measurements exceeded chamber size or function as
defined for normal adult Boxers as a left ventricular FS% <21%,
left ventricular internal diastolic dimension (LVIDD) >4.8 cm
and a left ventricular systolic internal dimension (LVIDS)
>3.3 cm. These values were chosen because they either exceed
(LVIDD and LVIDS) or fail to meet (FS%) the reference range
as defined for normal adult Boxer dogs.8
Dogs with echocardiographic abnormalities suggestive of con-
genital heart disease were excluded from the study. In addition,
dogs with indicatons of possible systemic disease were more thor-
oughly evaluated based on clinical suspicion (physical examina-
tion or historical findings). Degree of evaluation was dependent
on the clinician’s opinion and may have included a CBC and
serum biochemistry, thoracic radiography, and abdominal ultra-
sonography. Dogs with evidence of serious systemic disease were
excluded from the study. Serum thyroid hormone measurements
were not required for inclusion in this investigation.
The AECG was placed, and the dog was sent home in order
to allow monitoring of the dog’s cardiac electrical activity in its
normal environment. The owners were encouraged to maintain
the dog’s normal activity level and the monitor was removed
after 25 hours. The analysis was performed by a technician in a
prospective, user-interactive method under the guidance of a vet-
erinary cardiologist.a Recordings with <20 hours of readable data
were excluded. The total number of VPCs/24 h was tabulated
and the ventricular arrhythmia complexity was graded numeri-
cally from 0 to 4 as follows: 0 = no VPCs, 1 = single VPCs,
2 = bigeminy, trigeminy, 3 = couplets, triplets, 4 = R on T phe-
nomenon or ventricular tachycardia. The highest grade observed
was the grade assigned.
Dogs were considered affected with ARVC if they had ≥300
VPCs/24 h on at least 1 Holter monitoring without an obvious
cause for the arrhythmia and had been evaluated at least 2 years
sequentially. The number of VPCs used for diagnosis was based
on Animal Registry of Certified Health (ARCH) (http://www.
archcertify.org/) guidelines presented at the American College of
Veterinary Internal Medicine Forum in 2009 (unpublished data).
Briefly, the guidelines are as follows: the presence of 0–50 VPCs/
24 h, predominantly single, monomorphic is interpreted as nor-
mal; the presence of 50–300 VPCs/24 h suggests that Boxer
ARVC cannot be conclusively diagnosed or ruled out at this time
and the presence of runs of ventricular tachycardia or >300
VPCs/24 h suggests Boxer ARVC. Dogs were considered unaf-
fected by ARVC (controls) if they were ≥6 years of age, had been
followed up for at least 2 consecutive years and never had >50
VPCs/24 h on any Holter monitoring.
Dogs were placed on antiarrhythmic medication at the discre-
tion of the evaluating cardiologist. The decision to start an anti-
arrhythmic drug typically was made based on the presence of
syncope and the number of VPCs or complexity (grade) of the
arrhythmia. In some cases, owners elected not to treat the dogs.
There was no attempt to randomize or control treatment.
A cohort of 16 ARVC Boxers that had never received antiar-
rhythmic medications was evaluated as part of the combined
group as well as on an individual basis to evaluate annual varia-
tion in VPC number that occurred without the effect of antiar-
rhythmic medication.
Genotyping for the Boxer ARVC striatin deletion was per-
formed with DNA samples obtained from blood samples col-
lected in EDTA tubes. DNA was extracted from the sample
and evaluated by amplified fragment length polymorphism
(AFLP)-polymerase chain reaction (PCR) for the striatin dele-
tion.3 Standard PCR amplifications were carried out using a
cocktail of NH4SO4 amplification buffer, Taq DNA polymerase
(0.1 U/lL of reaction volume), 2.5 mM MgCl2, 12.5 lM of
each dNTP and 2.5 mM of each primer (the 50 end of the for-
ward primer labeled fluorescently with 56-FAM). Amplicons
then were evaluated by AFLP on a DNA analyzer.b Alleles
were scored using peak scanner softwareb according to fragment
size (352 bp for wildtype, 343 bp and 352 bp for positive het-
erozygote fragments and 343 bp for positive homozygous dele-
tion fragment).
Descriptive statistics were determined for age of the control
group, maximum number of VPCs and maximum grade of the
arrhythmia for the control group for all Holter monitoring per-
formed on an individual dog, age at detection of ≥300 VPCs in
each ARVC dog, number of VPCs detected the first time ≥300
VPCs were observed, annual change in VPC number for each
Holter monitoring in ARVC dogs, number of VPCs in years
before, and after the year in which ≥300 VPCs were detected for
dogs not on antiarrhythmic medication and percentage annual
change in FS%, LVIDD and LVIDS for the duration of partici-
pation in the study.
Survival was calculated for both the control and ARVC
dogs with Kaplan–Meier curves. Survival also was calculated
for the control dogs and compared to that of ARVC dogs
that had at ≥1,000 VPCs at some point during the study.
Because of the small group size and large number of dogs cen-
sored, survival was not calculated separately for the cohort of
16 dogs that had received not on an antiarrhythmic medica-
tion. Dogs were censored if they were still alive at final con-
tact, died of noncardiac cause, or were euthanized for
noncardiac reasons. To determine if there was bias in censor-
ing of the 2 groups, a Fisher’s test was done to compare cen-
soring between the 2 groups. An alpha of P = .05 was
considered to be significant.
Results
A total of 551 dogs were evaluated over of the span
of this 8-year study, although the number of annual
follow-up examinations varied with each subject.
Twenty-three dogs (4 male [1 intact, 3 castrated] and
19 female ([8 intact, 11 spayed]) made up the unaf-
fected control group. Median time for participation in
the study was 6 years (range, of 2–9). Median age for
dogs classified as unaffected was 7 years (range, 6–10).
The median maximum number of VPCs for all con-
trols for the duration of their participation in the
study was 12 (range, 4–32). The median grade of the
arrhythmia was 3 (range, 1–4). Ventricular size and
function were within normal limits as described for
adult Boxers.8 Seventeen of the 23 control Boxers were
genotyped, 5 (29%) were heterozygous for the striatin
mutation and 12 (71%) were negative.
Forty-nine (18 male [8 intact, 10 castrated] and 31
female [10 intact, 21 spayed]) dogs had ≥300 VPCs.
Sixteen (33%) of the 49 Boxers were syncopal at some
point during the study.
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Median time for participation in the study was
5 years (range, 3–8) and dogs were followed up for a
median of 3 years (range, 0–7) after the detection of
≥300 VPCS. Median age for detection of ≥300 VPCs
was 6 years (range, 1–11). Twenty-eight of the dogs
were followed up for ≥1 year (range, 0–7 years) before
they developed ≥300 VPCs. Median age for detection
of ≥300 VPCs in this group also was 6 (range, 2–11).
Median grade at first detection of ≥300 was 3
(range,1–4). Median number of VPCs at first detection
of ≥300 VPCs was 1,823 (range, 340–23,943) with 46
(94%) dogs eventually having ≥1000 VPCs/24 h.
Forty-three of 49 ARVC Boxers were genotyped.
Thirty-six were positive for the striatin deletion.
Twenty-six (61%) were heterozygous for the deletion,
10 (23%) were homozygous for the deletion, and 7
(16%) were negative.
Thirty-three (67%) ARVC Boxers were on some
type of antiarrhythmic medication (eg, atenolol, meto-
prolol, sotalol, procainamide, mexiletine, or a combi-
nation of ≥2 of these drugs) at some time during the
study and were excluded from additional arrhythmia
evaluation.
Sixteen Boxers with ARVC never received antiar-
rhythmic treatment during the course of the study and
were used for additional evaluation of annual change in
VPC number. The maximum number of VPCs the year
≥300 VPCs were detected ranged from 333 to 14,848/
24 h (median 1,190). The number of VPCs in the year
preceding detection of ≥300 ranged from 0 to 201 (med-
ian 45). The number of VPCs detected 1 year after ran-
ged from 1 to 29,240 (median 256) (Fig 1). The annual
variation in VPC number for these dogs for all years
evaluated ranged from a decrease of 7,699 VPCs/24 h to
an increase in 33,524 VPCs/24 h (median annual change
46 VPCs/24 h). Eight dogs of the 16 had <25 VPCs
(0–23) on an annual Holter monitoring at some point in
the years after initial detection of ≥300 VPCs, despite
receiving no antiarrhythmic treatment (Fig 2).
Forty-seven of the 49 dogs had normal myocardial
function for the duration of the study. Median annual
percentage change was 0 for both LVIDD (33 to
47.9% change) and LVIDS (57 to 62% change).
Median annual percentage change in FS was 2% (57
to 62%). Two dogs had myocardial dysfunction as
defined by decreased FS (11 and 17%, respectively)
without left ventricular dilatation. Both dogs had been
evaluated for at least 3 years before the decrease in
myocardial function and had been observed to have
gradual cardiac enlargement and a gradual decrease in
systolic function. Both of these dogs died suddenly.
One of these dogs was heterozygous for the striatin
mutation and the other was not genotyped. Four dogs
developed both diastolic and systolic dilatation (2 were
not genotyped, 1 was negative, and 1 was homozygous
for the deletion mutation) but maintained an FS ≥25%
for the duration of the study.
There was no difference in survival between the con-
trol and ARVC groups. The control group had a med-
ian survival of 10 years of age and the ARVC group
had a median survival of 11 years of age (Fig 3).
Sixty-four percent of the ARVC dogs were still alive at
the age of 9 years regardless of whether ≥300 or
≥1,000 VPCs was used as criteria for being affected.
The median survival time after detection of ≥300 VPCs
was 1528 days, and median survival after detection of
at least 1,000 VPCs was 1,754 days. Fewer dogs were
censored in the control group (4/23) than in the
ARVC group (15/49) but this difference was not statis-
tically significant (P = .77).
Fifteen ARVC dogs died suddenly, including the 2
dogs with decreased systolic function. One additional
dog with progressive ventricular dilatation and an FS
of 23% was euthanized for congestive heart failure.
Five dogs were euthanized for neoplastic causes and 5
dogs were euthanized for degenerative myelopathy or
other neurologic diseases. One dog each was euthanized
for refractory diabetes mellitus, liver failure, renal fail-
ure, and 2 for other unknown causes. None of the con-
trol dogs died of a cardiac cause but 4 were euthanized
because of degenerative myelopathy or neoplasia.
Discussion
The objective of this study was to prospectively
evaluate the natural history of Boxer dog ARVC.
Fig 1. Median number of ventricular premature complex (VPCs)
in the year before and after the year in which arrhythmogenic right
ventricular cardiomyopathy (ARVC) dogs had ≥300 VPCs/24 h as
well as the year in which ≥300 VPCs were first detected. Median
and ranges are presented in the boxes above each bar.
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Although Boxer ARVC is a familial disease and
many dogs have a causative genetic mutation that is
present since birth, it appears that most dogs do not
develop the phenotype until middle age. The evalua-
tion of 28 of the dogs in this study for ≥1 year before
they met the affected criteria illustrated that the
detection of ≥300 VPCs generally was not apparent
before 6 years of age. This observation is consistent
with the age-related penetrance of ARVC observed in
human beings, where it been suggested that age-
related penetrance may be because of progressive
exposure of the abnormal myocardium to mechanical
stress.9,10 It also has been determined in both human
beings and animals that endurance training may exac-
erbate disease, and it has been suggested that the dis-
ease may progress more slowly in individuals leading
a sedentary life, with myocardial injury accumulating
as part of the aging process.10–12
Our data also indicate that the development of
arrhythmias in Boxer ARVC may be fairly abrupt.
Affected dogs progressed from having a median of 41
VPCs/24 h, which generally would be interpreted as nor-
mal in this breed, to a median of 1,823 VPCs within a
year. Once the arrhythmia was detected, a considerable
yearly variation was observed. Several dogs returned to
what is considered normal at some point during the
study. These findings are consistent with a previous
study that identified >80% day-to-day variability in
VPC number in Boxers that had ≥500 VPCs.13 These
findings emphasize the difficulty in diagnosing Boxer
ARVC on a single Holter monitoring and suggest that a
single Holter monitoring may not be enough to conclu-
sively rule out the presence of disease for the purposes of
Fig 2. Change in number of ventricular premature complex (VPCs)/24 h over time. Each line represents 1 of 8 dogs that had an annual
VPC number of <25 VPCs after the initial detection of ≥300 VPCs, despite receiving no antiarrhythmic treatment. Large year-to-year
variability is noted.
Fig 3. Survival for control and arrhythmogenic right ventricular
cardiomyopathy (ARVC) dogs. Dogs were censored if they were
still alive at final contact, died of noncardiac cause, or were
euthanized for noncardiac reasons. There was no difference in
survival between the control and ARVC groups. The control
group had a median survival of 10 years and the ARVC group
had a median survival of 11 years.
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breed screening or diagnosis of a dog with suspicious
clinical signs. The development of more comprehensive
diagnostic criteria for this disease is warranted.
Both human beings and dogs with ARVC can
develop decreased systolic function and congestive
heart failure, but this was an uncommon finding in the
dogs studied here.6,9,10,14 In fact, the median percent-
age annual change in LVIDD and LVIDS was zero.
However, 2 dogs (4%) did develop progressive systolic
dysfunction. Both of these dogs died suddenly, which
is consistent with studies in both human beings and
dogs with ARVC that found that echocardiographical-
ly apparent left ventricular involvement is associated
with an adverse outcome.6,15,16
Although dogs with Boxer ARVC do die suddenly
and do develop congestive heart failure, the majority
of dogs in this study were still alive at 9 years of age
and did not have shorter survival than the control
dogs.1,2,4,6 The median survival after detection of ≥300
or ≥1,000 VPCs was 1,528 and 1,754 days, respec-
tively. This is quite a bit longer than what was previ-
ously described in a population of affected Boxers
from Spain, where the median survival time was 1 year
(range, 7–1,961 days).4 In that study, a retrospective
evaluation was performed by evaluating cases referred
to 3 hospitals in Spain, where a diagnosis of ARVC
was based on the presence of ≥1,000 VPCs/24 h. Dogs
were brought to the hospital for medical attention by
their owners and therefore may already have devel-
oped clinical signs or showed some indication of hav-
ing more advanced disease. In comparison, the dogs in
this study were recruited because of signalment (Boxer
dog >1 year of age) and over half of them were evalu-
ated at least 1 year before they met the diagnostic cri-
teria of ARVC. Therefore, the dogs in this study may
have been diagnosed at the earliest onset of disease
and may have had relatively longer survival. In addi-
tion, the dogs in the study from Spain may have had a
different etiology for ARVC than did the dogs in this
US study, which may be more likely to have a poor
prognosis. Finally, some of the dogs in this study were
receiving antiarrhythmic medication and this may or
may not have impacted prognosis. Because the study
was not designed to prospectively evaluate the impact
of treatment and a variety of different drugs and dos-
ages were used, it is difficult to determine the impact
of antiarrhythmic treatment on survival. Additional
studies in this area are warranted.
Forty-three of the 49 ARVC dogs in this study were
genotyped for the striatin deletion. Thirty-six (84%) of
the dogs were positive for the mutation, but 7 (16%)
dogs did not carry the mutation indicting at least 1 other
cardiac or systemic cause for the VPCs in these dogs. In
addition, 5 of the control dogs were heterozygous for
the striatin deletion, but did not demonstrate the ARVC
phenotype. This finding is consistent with the variable
penetrance of the disease observed in both humans and
dogs.3,9 In some human kindreds with ARVC muta-
tions, the penetrance is as low as 30% (ie, only 30% of
humans with the known causative mutation show the
disease).17 We have shown previously that the
penetrance of the striatin mutation in Boxer dogs with
ARVC is approximately 80%, so it is not surprising that
5 dogs in the control group were positive for the muta-
tion but did not show the phenotype.3 The mechanism
associated with incomplete penetrance in ARVC and
other forms of cardiomyopathy are poorly understood,
but likely involve a variety of factors including both
genetic modifiers and environmental influences.17
This study has several limitations. Although >500
dogs were enrolled in the study, many dogs did not fit
the criteria for inclusion in either the affected or unaf-
fected groups and could not be included in the final
analysis. In many cases, the number of VPCs on the
Holter monitoring did not place the dog clearly in
either the affected or unaffected group, or they
appeared to be unaffected but died from noncardiac
causes (eg, trauma, lymphoma) before they reached
6 years of age (the cut-off age for considering a dog
unaffected). Some dogs were lost to follow-up for vari-
ous reasons (eg, owner moved, dog was lost, dog was
sold) and did not return for annual evaluation. These
factors markedly limited the number of dogs that had
more than 1 annual evaluation, and ultimately the
numbers of dogs in the affected and control groups
were quite small. Evaluation of a larger number of
dogs in each group may have impacted the findings.
Females were overrepresented in both the affected
and unaffected groups. The reason for this finding is
unknown. Boxers were widely recruited from referring
veterinarians in the region as well as from local breed
clubs. Some of the participating dogs came from
breeding kennels where the number of female dogs
tends to exceed the number males.
The criterion used for inclusion in this study was the
presence of ≥300 VPCs/24 h. This number was based
on guidelines developed by a committee of board certi-
fied veterinary cardiologists for the Animal Health
Registry of Certified Health (ARCH) (http://www.
archcertify.org/) program and was presented at the
ACVIM Forum in 2009. However, the diagnosis of
ARVC in human beings typically is based on the pres-
ence of a combination of major or major and minor
findings from several different diagnostic categories
including global or regional myocardial dysfunction
and structural abnormalities, tissue characterization of
the ventricular wall, repolarization abnormalities,
depolarization or conduction abnormalities, arrhyth-
mias, and family history.18 Such diagnostic criteria
have not yet been established for veterinary medicine,
and access to some forms of diagnostic testing may be
limited and impractical. Many veterinary cardiologists
rely on the combination of signalment (adult Boxer)
and detection of an increased number of VPCs in the
absence of other underlying causes for the arrhythmia.
Although for the purposes of this study, we used
detection of ≥300 VPCs as a criterion, we reassessed
the survival data using a cut-off of ≥1,000 VPCs (as
used in a previous study) and 46/49 dogs still were
considered affected.4 It has been suggested that a num-
ber much lower than 300 VPCs/24 h may indicate dis-
ease.15 Holter monitoring in normal adult large breed
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dogs identified no more than a median of 2 VPCs/
24 h.19 In addition, a study in normal asymptomatic
Boxers identified a median of 97 VPCs.5,19 Although it
therefore is possible that a lower number of VPCs
actually may indicate disease, we believe that using a
cut-off of ≥300 VPCs/24 h was likely to identify dogs
that were truly abnormal. The inclusion criteria did
not weigh the impact of grade of arrhythmia, although
it was recorded. The median grade of arrhythmia for
both the control and ARVC dogs was 3 (range, 1–4).
The substantial overlap between the 2 groups with
regard to grade of arrhythmia could suggest that some
of the control dogs actually were affected. The pres-
ence of a small amount of a high-grade ventricular
arrhythmia in apparently normal dogs is not uncom-
mon. Two previous Holter studies of apparently
healthy (nonboxer) dogs have identified some high
grade (4) ventricular arrhythmias in normal dogs.19,20
The identification of higher grade arrhythmias in
apparently normal dogs is a poorly understood finding
that deserves further study. Importantly, both the
number of VPCs and the grade of arrhythmia should
be taken into consideration when evaluating an indi-
vidual dog for disease status.
Finally, there was no attempt to control antiarrhyth-
mic treatment in the dogs in this study. Use of differ-
ent antiarrhythmic drugs and different dosages of the
antiarrhythmic drugs could have impacted survival
results and deserves further study.
Despite the limitations of this study, these results
confirm that Boxer ARVC is a disease that typically
develops in the middle-aged Boxer dog and is fre-
quently associated with the striatin gene deletion. The
previously reported incomplete penetrance and age-
related penetrance of the striatin mutation were further
supported by this data, similar to what is observed in
mutations in human beings affected with ARVC. Clini-
cal signs including syncope are common in approxi-
mately 1/3 of the dogs and development of systolic
myocardial dysfunction is uncommon. In fact, most
dogs do not have any changes in cardiac size or func-
tion for the duration of their disease. Finally, although
cause of death is more frequently cardiac nature, the
prognosis of Boxer ARVC in many dogs actually is
quite good, with no apparent difference in overall sur-
vival from a control population.
Footnotes
a Delmar Accuplus, Irvine, CA
b Applied Biosystems, Foster City, CA
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